Moderna/Merck mRNA vaccine trial was for melanoma.
Results 'promising' results P2. 44% reduced recurrence compared to Keytruda mono.
Check out Immutep/Merck TACTI-Mel P1 trial. Oct 2018
Efti and Keytruda
Results promising too (small cohort 24 patients).
Disease control - 66%
Patients tumour shrinkage - 50%
NB - melanoma is particularly immuno-responsive and a crowded space for approved therapies.
Poster presentation of TACTI-mel
Conclusion section:-
2 patients with complete response
Supports hypotheses that combining APC activator with checkpoint inhibitor- synergy and clinical benefit
Further investigation of this combination is ongoing in NSCLC and HNSCC
Therefore focus moved to NSCLC/HNSCC as higher priority unmet need.
Efti - APC activator could be the idea partner to help turn 'cold' solid tumours 'hot' and boost performance of primary ICI's, chemo and others, including vaccine/virus drug candidates in clinical development.
Lag-3 and efti is only at the beginning of its commercial journey.
Moderna/Merck mRNA vaccine trial was for melanoma. Results...
-
- There are more pages in this discussion • 1,526 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |